Trump Announces 100% Tariffs on Pharmaceutical Imports

On September 26, 2025, President Donald Trump announced a significant trade policy change, imposing a 100% tariff on imported branded pharmaceuticals, effective October 1. This decision is part of a broader strategy to encourage domestic manufacturing, as companies that have begun construction on U.S. manufacturing plants will be exempt from these tariffs. The announcement also included a 25% tariff on heavy-duty trucks and various tariffs on kitchen and bathroom furniture.

The GuardianStocks cop one-two punchCNBCAsia stocks slide as Trump slaps on new tariffs, Fed cut bets recedeBloomberg

The immediate market response to Trump's tariff announcement was mixed. The pan-European Stoxx 600 index rose by 0.5% as investors assessed the implications of the new tariffs. However, shares of major pharmaceutical companies such as Denmark's Zealand Pharma and Novo Nordisk fell by 2.9% and 1.6%, respectively. In Asia, pharmaceutical stocks also experienced declines, with South Korean firms like Samsung Biologics and SK Biopharmaceuticals dropping by 1.6% and 2.6%.

Bloomberg

JP Morgan strategists noted that the potential impact of the tariffs could be manageable due to the ongoing shift towards U.S.-based manufacturing. They suggested that the tariffs could largely be avoided if companies expedite their domestic production plans.

The Guardian

The tariffs are expected to have far-reaching consequences for the pharmaceutical industry. In 2024, the U.S. imported nearly $233 billion in pharmaceutical products, and the imposition of these tariffs could lead to significant price increases for consumers. Critics, including Pascal Chan from the Canadian Chamber of Commerce, warned that the tariffs could exacerbate healthcare costs, potentially leading to shortages and rationing of essential medicines.

The Guardian

Major pharmaceutical companies, including AstraZeneca and Eli Lilly, had already announced plans to boost U.S. manufacturing in anticipation of potential tariffs. However, the sudden announcement of a 100% tariff caught many off guard, raising concerns about the feasibility of meeting the new requirements.

The Guardian

The announcement has drawn criticism from various stakeholders. Advocacy groups have expressed concerns that the tariffs could lead to higher drug prices, further straining the healthcare system. The U.S. Chamber of Commerce also opposed the tariffs, arguing that they could harm relationships with key trading partners, including Mexico and Canada, which are significant sources of pharmaceutical imports.

The Guardian

While the tariffs are set to take effect soon, there remains uncertainty regarding their implementation. It is unclear how the tariffs will apply to companies that already have manufacturing facilities in the U.S. Additionally, the legal justification for these tariffs has been questioned, as Trump cited national security concerns without providing detailed explanations.

The Guardian

As the October 1 deadline approaches, the pharmaceutical sector and investors will closely monitor the situation. Economic data releases, including inflation figures and mortgage lending statistics, are also expected to influence market sentiment in the coming days. The broader implications of these tariffs on U.S. trade relations and domestic manufacturing capabilities will continue to unfold as stakeholders respond to the new trade landscape.

CNBC

• “If [Trump] goes through with these tariffs, people across the country will die.” — 314 Action, U.S. advocacy group

The Guardian

• “The sectoral tariffs are here to stay because those have proven to be more legally sound than the emergency tariffs that the lower courts judged to be illegal,” — Carol Kong, Economist, Commonwealth Bank of Australia

Reuters

• “We need our Truckers to be financially healthy and strong, for many reasons, but above all else, for National Security purposes!” — Donald Trump, President of the United States

The Guardian